Buy Norflurazepam Pellets 5mg

Product Overview

Norflurazepam Pellets 5mg (CAS 2886-65-9) supply researchers with a desalkyl-flurazepam analog reference standard in convenient tablet format, optimized for forensic toxicology screening, LC-MS method validation, and benzodiazepine metabolite profiling within professional laboratory frameworks. This generic, brandless compound achieves ≥98% purity through controlled synthesis and recrystallization, ensuring batch consistency essential for reproducible quantitative analysis across biological matrices. The scored 5mg tablet design facilitates accurate dosing for calibration curves and internal standard preparation, supporting academic research institutions, contract laboratories, and regulatory testing facilities worldwide. Exclusively manufactured for non-clinical research, these pellets conform to WooCommerce eCommerce compliance and international standards for research chemical distribution. Investigators employ this format for establishing method LODs below 1 ng/mL, building MS spectral libraries, and conducting stability studies where dosage uniformity determines analytical reliability. Validated ICH stability supports multi-year utility in longitudinal NPS monitoring programs. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Norflurazepam carries CAS 2886-65-9, molecular formula C₁₅H₁₀ClFN₂O, and molecular weight 288.7 g/mol. IUPAC name: 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one. Synonyms include N-desalkylflurazepam, norfludiazepam, Ro 05-4435. Classified as a 1,4-benzodiazepin-2-one with 7-chloro and 5-(2-fluorophenyl) substitution, it serves as an analytical reference for ESI-MS/MS transitions (m/z 289→241/140), ¹H-NMR (DMSO-d6 7.2-8.0 ppm aromatic), and RP-HPLC retention matching. Desalkyl modification distinguishes LC behavior (k’ 7.2 C18) from N-alkylated parents, enabling forensic differentiation.

Chemical & Physical Characteristics

Norflurazepam Pellets 5mg feature compressed white tablets housing Form I crystalline active (D50 10-15 μm). Solubility exceeds 25 mg/mL DMSO, 15 mg/mL MeOH/ACN, pH 7.4 aqueous 0.06 mg/mL. DSC Tm 235°C (ΔH 29 kJ/mol), logP 3.27, pKa 2.2/10.8. Excipients ensure <2 min disintegration, friability 0.5%, hardness 5 kp. UV ε268nm 28,500 M⁻¹cm⁻¹ supports 0.1 µg/mL detection.

Purity & Analytical Verification

Batches ≥98% purity confirmed by RP-HPLC (>98.6% area), qNMR (99.1% w/w), HRMS (m/z 288.0466 [M+H]⁺ <1 ppm), GC-FID residuals (<3000 ppm solvents). COAs detail desfluoro impurity <0.08%, metals <10 ppm, uniformity USP <905> ≤1.9% RSD. Linearity r² 0.9998 0.05-100 µg/mL.

Quality Control & Batch Integrity

End-to-end traceability from fluorobenzophenone cyclization through tableting. NIR blend uniformity RSD<1.4%, ICH stability 60 months (25°C/60%RH). Retained composites validate 7-year retest.

Safety, Handling & Laboratory Precautions

Fume hood (>100 fpm), nitrile gloves (15 mil), goggles, N95. Static-free weighing, secondary containment. SDS H302+H315+H319; spill sorbent/HEPA.

Packaging, Labeling & Storage

Amber HDPE/PTFE vials, desiccated, GHS CAS 2886-65-9 labels. Store -20°C (>5 years); 15-25°C 24 months.

Intended Research Use & Market Positioning

Forensic quantitation (LOD 0.5 ng/mL), metabolite ratios, method validation. Cost-effective CRM alternative for high-throughput screening.

Ordering, Availability & Fulfillment

Immediate stock, 24h dispatch, tracked global shipping, COA access.

Legal & Regulatory Disclaimer

Norflurazepam Pellets 5mg (CAS 2886-65-9) for laboratory research only. Not for human or veterinary use. Not for clinical, diagnostic, consumptive applications. Buyers ensure compliance.